Clinical trial

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2024-08-27

PhasePHASE2

Study timeline

Study start (actual)2024-08-27Date precision: day

Registry last updated2026-09-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancerunresolved

Interventions

VolrustomigDRUG

CarboplatinDRUG · verified · RxNorm: carboplatin

PemetrexedDRUG · verified · RxNorm: pemetrexed

RamucirumabDRUG · verified · RxNorm: ramucirumab

PaclitaxelDRUG · verified · RxNorm: paclitaxel

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

LisbonPortugal3 TaipeiTaiwan2 ValenciaSpain2 AthensGreece2 Los AngelesCalifornia, United States1 SeoulSouth Korea1 MadridSpain1 BarcelonaSpain1 MilanItaly1 Chapel HillNorth Carolina, United States1 BeijingChina1 MontpellierFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06448754 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.